BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced its participation in the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo from November 19-23 in Vancouver. Through its brand Asuragen, the company will showcase new research products for breast cancer monitoring and carrier screening at booth #811. The event features workshops on the QuantideX® qPCR ESR1 exoMutation Kit and AmplideX® Nanopore Carrier Plus Kit, along with discussions on LDT compliance. Multiple research posters will be presented covering topics including ESR1 mutations detection, complex variant genotyping, and molecular testing advances.
Positive
- Showcasing new diagnostic products for breast cancer monitoring and carrier screening
- QuantideX® qPCR ESR1 exoMutation Kit achieves high analytical sensitivity of ≤0.1% across 11 ESR1 mutations
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TECH declined 4.46%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees
"The Association for Molecular Pathology is a leading voice in the world of clinical molecular testing. We look forward to its meeting every year to discuss the latest advances in molecular diagnostics and how they can be deployed for improved laboratory outcomes," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "This year, we're excited to highlight important new products that will help labs streamline data collection and analysis in critical areas including metastatic breast cancer and carrier screening."
At the AMP 2024 Annual Meeting & Expo, Asuragen will host, sponsor, or participate in a number of activities and presentations.
ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCR
This workshop will showcase the design and performance of the QuantideX® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve analytical sensitivity of ≤
Speaker: Brian Haynes, PhD, Bio-Techne Diagnostics Division
Date and time: Wednesday, November 20, 3:00-3:50 PM PST
Location: Room 212/213
Long-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated Genes
This workshop will focus on the design and performance of the AmplideX® Nanopore Carrier Plus Kit, combining AmplideX PCR chemistry with the Oxford Nanopore® platform to identify the most challenging genetic alterations like CNVs, large inversions, and pseudogenes using a consolidated workflow.
Speaker: Paul A. Wadsworth, MD, PhD, Resident Physician, Pathology, Stanford University
Date and time: Wednesday, November 20, 12:00-12:50 PM PST
Location: Room 114/115
Fireside Chat: LDT Compliance in an Uncertain Environment
With so much uncertainty around the FDA's laboratory-developed test (LDT) rule, it is challenging for laboratory leaders to make firm plans for how to achieve compliance. This session will consider three different tactical approaches for stage I of the rule: a) labs actively preparing for compliance; b) labs preparing, but cautiously using resources; and c) labs that are taking a 'wait and see' approach.
Discussion Leader: Jordan Laser, MD, Asuragen
Date and time: Wednesday, November 20, 5:15-6:15 PM PST
Location: Room 211
POSTERS
Verification of an RT-qPCR Assay System for Liquid Biopsy Surveillance of Treatment-Resistant ESR1 Mutations
Presenting author: Blaine Caughron, Asuragen
Poster info: G095, Genetics; Saturday, November 23, 9:15 am -10:15 am
Verification of an Amplification-Based Nanopore Sequencing Assay and Software to Genotype Complex, Clinically-Relevant Variants in 11 Hard-to-Decipher Genes with High Carrier Frequencies
Presenting author: Connor A. Parker, Asuragen
Poster info: G094, Genetics; Friday, November 22, 9:15 am -10:15 am
Freeze-Dried, Worry Thawed: Armored RNA New Lyophilized Controls Offer Potential to Advance Molecular Testing in Resource Limited Settings
Presenting author: Deepa Eveleigh, Asuragen
Poster info: ID046, Infectious Disease; Friday, November 22, 9:15 am -10:15 am
Beta Evaluation of a Panel of 11 Challenging Genes Using ONT/AmplideX Chemistry
Presenting author: Anne-Sophie Lebre, Professor of Human Genetics & Clinical Molecular Geneticist, Reims Medical School & University Hospital
Poster info: G013, Genetics; Saturday, November 23, 9:15am -10:15am
Stop by the Asuragen booth (#811) to learn more about the company's products for clinical laboratories. We will also be providing free, professional-quality headshots to all AMP attendees who visit our booth on Thursday or Friday.
For more information about Asuragen's AMP 2024 activities, please visit https://www.bio-techne.com/about/events/association-molecular-pathology.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html
SOURCE Bio-Techne Corporation
FAQ
What products will Bio-Techne (TECH) showcase at AMP 2024?
When and where is Bio-Techne (TECH) presenting at AMP 2024?
What is the sensitivity of Bio-Techne's (TECH) QuantideX ESR1 mutation detection kit?
